Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Stock Traded Much Higher Than Its 50 Day Moving Average


The stock is trading at $1.84 which is quite a bit higher than the 50 day moving average of $1.52 and quite a bit above the 200 day moving average of $1.35. The 50 day moving average was up $0.32 whereas the 200 day average was up by +35.96%. Pluristem Therapeutics, Inc. shares had a trading volume of 348K by the end of trading on Tuesday. Shares saw a steep increase in trading volume of 188.95% over the normal average daily volume.

Traders are feeling more bearish on Pluristem Therapeutics, Inc. of late if you consider the motion in short interest. The company recorded a rise in short interest from September 15, 2017 to September 29, 2017 of 46.99%. Short interest grew 393,224 over that timeframe. With short interest at 1,230,052 and short average daily volume at 1,026,250, the short-interest ratio is 1.0 and the percentage of shorted shares was 0.01% on September 29.

The following firms have recently changed their position in PSTI. As of quarter end Psagot Investment House Ltd. had sold 3,719 shares trimming its position 34.1%. The value of the total investment in Pluristem Therapeutics, Inc. decreased from $13,000 to $9,000 a change of $4,000 for the reporting period. As of the end of the quarter Focused Wealth Management, Inc had acquired a total of 10,000 shares growing its holdings by 100.0%. The value of the investment in Pluristem Therapeutics, Inc. went from $12,000 to $26,000 a change of 116.7% since the last quarter.

As of quarter end Jane Street Group, LLC had acquired 122,471 shares growing its stake by 112.5%. The value of the investment in (PSTI) increased from $134,000 to $296,000 increasing 120.9% quarter to quarter. As of the end of the quarter Ubs Group Ag had acquired 592,557 shares growing its stake by 274.5%. The value of the investment in PSTI went from $265,000 to $1,035,000 a change of 290.6% quarter over quarter.

On October 6 analysts at Seaport Global released its first research report on the stock by announcing an initial rating of “Buy”.

In the last earnings report the EPS was $-0.32 and is projected to be $-0.35 for the current year with 97,473,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $-0.09 and the next full year EPS is projected to be $-0.34.

Pluristem Therapeutics Inc., launched on May 10, 2001, is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Business’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. The Business’s operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Business’s products include PLX-PAD and PLX R18. The Business’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Business’s PLX products are administered using a standard needle and syringe. The Business’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases..